Indian Generics Face Lower Third-Quarter Income Without New Launches
This article was originally published in PharmAsia News
Executive Summary
Increasing competition and pressures in the United States and Europe to hold down the price of generic drugs threaten to reduce the income reports of Indian pharmaceuticals for the third quarter of 2007. The reduction also is expected in part because of lower income for authorized generics and the effects of a strong rupee. A Sarabjit Kour Nangra research vice president noted no new products were launched in India during the third quarter. (Click here for more